Expertise in
7
conditions

Dr. Paul B. Gilman

Hematology Oncology
100 Lancaster Ave, Main Line Oncology Hematology Associates, 
Wynnewood, PA 
Expertise in
7
conditions
100 Lancaster Ave, Main Line Oncology Hematology Associates, 
Wynnewood, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Paul Gilman is a Hematologist Oncology provider in Wynnewood, Pennsylvania. Dr. Gilman is highly rated in 7 conditions, according to our data. His top areas of expertise are Angiosarcoma, Breast Cancer, Paget Disease of the Breast, Vertebroplasty, and Bone Graft.

His clinical research consists of co-authoring 13 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in PA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

100 Lancaster Ave, Main Line Oncology Hematology Associates, Wynnewood, PA 19096

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy
Enrollment Status: Completed
Publish Date: November 12, 2025
Intervention Type: Drug, Radiation
Study Drugs: Cisplatin, Carboplatin, Paclitaxel
Study Phase: Phase 3
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: April 03, 2023
Intervention Type: Drug, Biological
Study Drugs: Nivolumab, Cisplatin, Pemetrexed Disodium, Gemcitabine Hydrochloride
Study Phase: Phase 2
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Enrollment Status: Unknown
Publish Date: March 29, 2023
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
View 4 Less Clinical Trials

13 Total Publications

Combination CBD/THC in the management of chemotherapy-induced peripheral neuropathy: a randomized double blind controlled trial.
Combination CBD/THC in the management of chemotherapy-induced peripheral neuropathy: a randomized double blind controlled trial.
Journal: Frontiers in oncology
Published: March 08, 2025
Similar Doctors
Expertise in
25
conditions
Dr. Pierluigi Porcu
Hematology Oncology | Oncology | Hematology
Expertise in
25
conditions
Dr. Pierluigi Porcu
Hematology Oncology | Oncology | Hematology

Jefferson University Physicians

925 Chestnut St, Suite 3, 
Philadelphia, PA 
 (6.2 miles away)
215-955-8874
Languages Spoken:
English
See accepted insurances

Pierluigi Porcu is a Hematologist Oncology specialist and an Oncologist in Philadelphia, Pennsylvania. Dr. Porcu is highly rated in 25 conditions, according to our data. His top areas of expertise are T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
11
conditions
Dr. Anita J. Kumar
Hematology Oncology
Expertise in
11
conditions
Dr. Anita J. Kumar
Hematology Oncology
3400 Spruce Street, 16 Penn Tower, 
Philadelphia, PA 
 (4.5 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances

Anita Kumar is a Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Kumar is highly rated in 11 conditions, according to our data. Her top areas of expertise are Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
27
conditions
Dr. Arthur P. Staddon
Hematology Oncology
Expertise in
27
conditions
Dr. Arthur P. Staddon
Hematology Oncology
230 W Washington Sq, 2nd Floor, 
Philadelphia, PA 
 (6.4 miles away)
215-829-6088
Languages Spoken:
English
See accepted insurances

Arthur Staddon is a Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Staddon is highly rated in 27 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Rhabdomyosarcoma, Alveolar Soft Part Sarcoma, and Synovial Sarcoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gilman's expertise for a condition
ConditionClose
    View All 43 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile